Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
Adenosine Monophosphate / administration & dosage
-
Adenosine Monophosphate / adverse effects
-
Adenosine Monophosphate / analogs & derivatives
-
Alanine / administration & dosage
-
Alanine / adverse effects
-
Alanine / analogs & derivatives
-
Anti-Infective Agents / administration & dosage
-
Anti-Infective Agents / adverse effects*
-
Azithromycin / administration & dosage
-
Azithromycin / adverse effects
-
Betacoronavirus*
-
COVID-19
-
COVID-19 Drug Treatment
-
Cardiovascular Diseases / chemically induced*
-
Coronavirus Infections / drug therapy*
-
Drug Combinations
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / adverse effects*
-
Humans
-
Hydroxychloroquine / administration & dosage
-
Hydroxychloroquine / adverse effects
-
Lopinavir / therapeutic use
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Ritonavir / therapeutic use
-
SARS-CoV-2
Substances
-
Anti-Infective Agents
-
Drug Combinations
-
Enzyme Inhibitors
-
lopinavir-ritonavir drug combination
-
Lopinavir
-
remdesivir
-
Adenosine Monophosphate
-
Hydroxychloroquine
-
Azithromycin
-
Ritonavir
-
Alanine